Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Neurology Department, Alrijne Hospital, Leiderdorp, The Netherlands.
CNS Drugs. 2020 Feb;34(2):171-184. doi: 10.1007/s40263-019-00696-2.
Cluster headache is characterised by attacks of excruciating unilateral headache or facial pain lasting 15 min to 3 h and is seen as one of the most intense forms of pain. Cluster headache attacks are accompanied by ipsilateral autonomic symptoms such as ptosis, miosis, redness or flushing of the face, nasal congestion, rhinorrhoea, peri-orbital swelling and/or restlessness or agitation. Cluster headache treatment entails fast-acting abortive treatment, transitional treatment and preventive treatment. The primary goal of prophylactic and transitional treatment is to achieve attack freedom, although this is not always possible. Subcutaneous sumatriptan and high-flow oxygen are the most proven abortive treatments for cluster headache attacks, but other treatment options such as intranasal triptans may be effective. Verapamil and lithium are the preventive drugs of first choice and the most widely used in first-line preventive treatment. Given its possible cardiac side effects, electrocardiogram (ECG) is recommended before treating with verapamil. Liver and kidney functioning should be evaluated before and during treatment with lithium. If verapamil and lithium are ineffective, contraindicated or discontinued because of side effects, the second choice is topiramate. If all these drugs fail, other options with lower levels of evidence are available (e.g. melatonin, clomiphene, dihydroergotamine, pizotifen). However, since the evidence level is low, we also recommend considering one of several neuromodulatory options in patients with refractory chronic cluster headache. A new addition to the preventive treatment options in episodic cluster headache is galcanezumab, although the long-term effects remain unknown. Since effective preventive treatment can take several weeks to titrate, transitional treatment can be of great importance in the treatment of cluster headache. At present, greater occipital nerve injection is the most proven transitional treatment. Other options are high-dose prednisone or frovatriptan.
丛集性头痛的特点是发作性单侧头痛或面部疼痛,持续 15 分钟至 3 小时,被认为是最剧烈的疼痛形式之一。丛集性头痛发作时伴有同侧自主神经症状,如眼睑下垂、瞳孔缩小、面部发红或潮红、鼻塞、流涕、眶周肿胀和/或不安或激动。丛集性头痛的治疗包括快速缓解的治疗、过渡治疗和预防性治疗。预防性和过渡性治疗的主要目标是实现无发作,但并非总是如此。皮下舒马曲坦和高流量氧气是治疗丛集性头痛发作最有效的缓解药物,但其他治疗选择,如鼻内曲坦,也可能有效。维拉帕米和锂是首选的预防药物,也是一线预防治疗中最常用的药物。鉴于其可能的心脏副作用,在使用维拉帕米治疗前建议进行心电图(ECG)检查。在开始锂治疗前和治疗期间应评估肝肾功能。如果维拉帕米和锂无效、禁忌或因副作用而停用,二线药物是托吡酯。如果所有这些药物都失败了,还有其他证据水平较低的选择(例如褪黑素、氯米芬、二氢麦角胺、哌替啶)。然而,由于证据水平较低,我们还建议在难治性慢性丛集性头痛患者中考虑几种神经调节选择之一。加奈珠单抗是治疗发作性丛集性头痛的预防治疗的新选择,尽管其长期效果尚不清楚。由于有效的预防性治疗可能需要数周时间来滴定,过渡性治疗在丛集性头痛的治疗中非常重要。目前,枕大神经注射是最有效的过渡性治疗。其他选择是大剂量泼尼松或氟伐曲坦。